Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1991 May 1;173(5):1193–1203. doi: 10.1084/jem.173.5.1193

Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice

PMCID: PMC2118864  PMID: 2022926

Abstract

DBA/2 mice were injected intravenously with 2 x 10(6) 3C18 Friend erythroleukemia cells (FLC), a cell line resistant to interferon alpha/beta (IFN-alpha/beta). Although daily administration of mouse IFN- alpha/beta markedly increased the mean survival time, most IFN-treated mice continued to harbor FLC in different organs. To investigate the mechanisms responsible for this persistent suppression of FLC growth in IFN-treated mice, we undertook a series of adoptive transfer experiments with sera and spleen cells. Sera from FLC-injected, IFN- treated mice were very effective in conferring protection on DBA/2 mice even when injected systemically (intravenously) 18-24 h before intravenous challenge with FLC. These sera also exhibited antitumor activity when injected subcutaneously or intraperitoneally together with FLC. The protective factor in serum was shown to be an immunoglobulin. FLC-injected, IFN-treated mice developed antibodies to FLC demonstrable by radioimmunoassay and complement-dependent cytotoxicity. Sera from these mice recognized a specific 65-kD FLC membrane antigen(s) not detectable on membrane extracts from RBL-5 or ESb tumor cells, or on normal spleen cells. FLC-injected, IFN-treated mice also developed a specific cellular response demonstrable by transfer of protection with spleen cells injected intravenously or subcutaneously. Analysis of the responsible spleen cell populations indicated that the effector cells were neither T nor B cells. These results demonstrating the importance of host humoral and cellular immune mechanisms in the persistent suppression of FLC in IFN-treated mice may be relevant to the use of IFN-alpha/beta in patients in whom tumors may regress and tumor cells may then remain latent for extended periods of time.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Affabris E., Jemma C., Rossi G. B. Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain. Virology. 1982 Jul 30;120(2):441–452. doi: 10.1016/0042-6822(82)90044-7. [DOI] [PubMed] [Google Scholar]
  2. Aguet M., Vignaux F., Fridman W. H., Gresser I. Enhancement of Fc gamma receptor expression in interferon-treated mice. Eur J Immunol. 1981 Nov;11(11):926–930. doi: 10.1002/eji.1830111114. [DOI] [PubMed] [Google Scholar]
  3. Bander N. H., Finstad C. L., Cordon-Cardo C., Ramsawak R. D., Vaughan E. D., Jr, Whitmore W. F., Jr, Oettgen H. F., Melamed M. R., Old L. J. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res. 1989 Dec 1;49(23):6774–6780. [PubMed] [Google Scholar]
  4. Belardelli F., Ferrantini M., Maury C., Santurbano L., Gresser I. Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize. Int J Cancer. 1984 Sep 15;34(3):389–395. doi: 10.1002/ijc.2910340316. [DOI] [PubMed] [Google Scholar]
  5. Belardelli F., Gresser I., Maury C., Maunoury M. T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I. Int J Cancer. 1982 Dec 15;30(6):813–820. doi: 10.1002/ijc.2910300621. [DOI] [PubMed] [Google Scholar]
  6. Brouty-Boyé D., Gresser I. Reversibility of the transformed and neoplastic phenotype. I. Progressive reversion of the phenotype of X-ray-transformed C3H/10T1/2 cells under prolonged treatment with interferon. Int J Cancer. 1981 Aug 15;28(2):165–173. doi: 10.1002/ijc.2910280209. [DOI] [PubMed] [Google Scholar]
  7. Brouty-Boyé D., Mogensen K. E., Gresser I. Effects of long-term treatment of human carcinoma cells with interferon alpha. Eur J Cancer Clin Oncol. 1985 Apr;21(4):507–514. doi: 10.1016/0277-5379(85)90045-8. [DOI] [PubMed] [Google Scholar]
  8. Dialynas D. P., Quan Z. S., Wall K. A., Pierres A., Quintáns J., Loken M. R., Pierres M., Fitch F. W. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol. 1983 Nov;131(5):2445–2451. [PubMed] [Google Scholar]
  9. Elia G., Ferrantini M., Belardelli F., Proietti E., Gresser I., Amici C., Benedetto A. Wheat germ agglutinin-binding protein changes in highly malignant Friend leukemia cells metastasizing to the liver. Clin Exp Metastasis. 1988 Sep-Oct;6(5):347–362. doi: 10.1007/BF01760571. [DOI] [PubMed] [Google Scholar]
  10. Gazitt Y., Friend C. Synthesis and phosphorylation of plasma membrane proteins of Friend erythroleukemia cells induced to differentiate. Cancer Res. 1981 Mar;41(3):1064–1069. [PubMed] [Google Scholar]
  11. Gresser I., Belardelli F., Maury C., Tovey M. G., Maunoury M. T. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens. Int J Cancer. 1986 Aug 15;38(2):251–257. doi: 10.1002/ijc.2910380216. [DOI] [PubMed] [Google Scholar]
  12. Gresser I., Maury C., Belardelli F. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases. Int J Cancer. 1987 Jun 15;39(6):789–792. doi: 10.1002/ijc.2910390623. [DOI] [PubMed] [Google Scholar]
  13. Gresser I., Maury C., Belardelli F., Maunoury M. T., Machover D. Effectiveness of mouse interferon alpha/beta compared to single-agent chemotherapy in increasing survival time of mice after intravenous inoculation of Friend erythroleukemia cells. J Natl Cancer Inst. 1988 Mar 16;80(2):126–131. doi: 10.1093/jnci/80.2.126. [DOI] [PubMed] [Google Scholar]
  14. Gresser I., Maury C., Carnaud C., De Maeyer E., Maunoury M. T., Belardelli F. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases. Int J Cancer. 1990 Sep 15;46(3):468–474. doi: 10.1002/ijc.2910460324. [DOI] [PubMed] [Google Scholar]
  15. Gresser I., Maury C., Woodrow D., Moss J., Grütter M. G., Vignaux F., Belardelli F., Maunoury M. T. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells. Int J Cancer. 1988 Jan 15;41(1):135–142. doi: 10.1002/ijc.2910410124. [DOI] [PubMed] [Google Scholar]
  16. Hellström I., Brankovan V., Hellström K. E. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1499–1502. doi: 10.1073/pnas.82.5.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Ledbetter J. A., Herzenberg L. A. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev. 1979;47:63–90. doi: 10.1111/j.1600-065x.1979.tb00289.x. [DOI] [PubMed] [Google Scholar]
  19. Locardi C., Belardelli F., Federico M., Romeo G., Affabris E., Gresser I. Effect of mouse interferon alpha/beta on the expression of H-2 (class I) antigens and on the levels of 2'-5' oligoadenylate synthetase activity in interferon-sensitive and interferon-resistant Friend leukemia cell tumors in mice. J Biol Regul Homeost Agents. 1987 Oct-Dec;1(4):189–194. [PubMed] [Google Scholar]
  20. McGrath M. S., Pillemer E., Weissman I. L. Murine leukaemogenesis: monoclonal antibodies to T-cell determinants arrest T-lymphoma cell proliferation. Nature. 1980 May 22;285(5762):259–261. doi: 10.1038/285259a0. [DOI] [PubMed] [Google Scholar]
  21. Mifune K., Mannen K., Cho S., Narahara H. Enhanced antibody responses in mice by combined administration of interferon with rabies vaccine. Arch Virol. 1987;94(3-4):287–295. doi: 10.1007/BF01310721. [DOI] [PubMed] [Google Scholar]
  22. Oppi C., Fiorucci G., Ferrantini M., Battistini A., Belardelli F. Friend murine leukemia virus and spleen focus-forming virus expression in highly malignant interferon-sensitive and interferon-resistant Friend leukemia cells. Virology. 1986 Apr 30;150(2):390–401. doi: 10.1016/0042-6822(86)90304-1. [DOI] [PubMed] [Google Scholar]
  23. Samid D., Chang E. H., Friedman R. M. Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun. 1984 Feb 29;119(1):21–28. doi: 10.1016/0006-291x(84)91612-7. [DOI] [PubMed] [Google Scholar]
  24. Sarmiento M., Glasebrook A. L., Fitch F. W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol. 1980 Dec;125(6):2665–2672. [PubMed] [Google Scholar]
  25. Schirrmacher V., Shantz G., Clauer K., Komitowski D., Zimmermann H. P., Lohmann-Matthes M. L. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo. Int J Cancer. 1979 Feb;23(2):233–244. doi: 10.1002/ijc.2910230215. [DOI] [PubMed] [Google Scholar]
  26. Strander H. Interferon treatment of human neoplasia. Adv Cancer Res. 1986;46:1–265. [PubMed] [Google Scholar]
  27. Tovey M. G., Begon-Lours J., Gresser I. A method for the large scale production of potent interferon preparations. Proc Soc Exp Biol Med. 1974 Jul;146(3):809–815. doi: 10.3181/00379727-146-38196. [DOI] [PubMed] [Google Scholar]
  28. Vignaux F., Gresser I., Fridman W. H. Effect of virus-induced interferon on the antibody response of suckling and adult mice. Eur J Immunol. 1980 Oct;10(10):767–772. doi: 10.1002/eji.1830101008. [DOI] [PubMed] [Google Scholar]
  29. Yagoda A., Bander N. H. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int. 1989;44(6):338–345. doi: 10.1159/000281537. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES